Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.